Cargando…
MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis
Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelia...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947565/ https://www.ncbi.nlm.nih.gov/pubmed/31847094 http://dx.doi.org/10.3390/jcm8122199 |
_version_ | 1783485579664556032 |
---|---|
author | Solly, Emma L. Dimasi, Catherine G. Bursill, Christina A. Psaltis, Peter J. Tan, Joanne T. M. |
author_facet | Solly, Emma L. Dimasi, Catherine G. Bursill, Christina A. Psaltis, Peter J. Tan, Joanne T. M. |
author_sort | Solly, Emma L. |
collection | PubMed |
description | Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelial cells, smooth muscle cells and macrophages that promote plaque development and progression. While there has been significant therapeutic advancement, there remains a gap where novel therapeutic approaches can complement current therapies to provide a holistic approach for treating atherosclerosis to orchestrate the regulation of complex signalling networks across multiple cell types and different stages of disease progression. MicroRNAs (miRNAs) are emerging as important post-transcriptional regulators of a suite of molecular signalling pathways and pathophysiological cellular effects. Furthermore, circulating miRNAs have emerged as a new class of disease biomarkers to better inform clinical diagnosis and provide new avenues for personalised therapies. This review focusses on recent insights into the potential role of miRNAs both as therapeutic targets in the regulation of the most influential processes that govern atherosclerosis and as clinical biomarkers that may be reflective of disease severity, highlighting the potential theranostic (therapeutic and diagnostic) properties of miRNAs in the management of cardiovascular disease. |
format | Online Article Text |
id | pubmed-6947565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69475652020-01-13 MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis Solly, Emma L. Dimasi, Catherine G. Bursill, Christina A. Psaltis, Peter J. Tan, Joanne T. M. J Clin Med Review Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelial cells, smooth muscle cells and macrophages that promote plaque development and progression. While there has been significant therapeutic advancement, there remains a gap where novel therapeutic approaches can complement current therapies to provide a holistic approach for treating atherosclerosis to orchestrate the regulation of complex signalling networks across multiple cell types and different stages of disease progression. MicroRNAs (miRNAs) are emerging as important post-transcriptional regulators of a suite of molecular signalling pathways and pathophysiological cellular effects. Furthermore, circulating miRNAs have emerged as a new class of disease biomarkers to better inform clinical diagnosis and provide new avenues for personalised therapies. This review focusses on recent insights into the potential role of miRNAs both as therapeutic targets in the regulation of the most influential processes that govern atherosclerosis and as clinical biomarkers that may be reflective of disease severity, highlighting the potential theranostic (therapeutic and diagnostic) properties of miRNAs in the management of cardiovascular disease. MDPI 2019-12-13 /pmc/articles/PMC6947565/ /pubmed/31847094 http://dx.doi.org/10.3390/jcm8122199 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Solly, Emma L. Dimasi, Catherine G. Bursill, Christina A. Psaltis, Peter J. Tan, Joanne T. M. MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis |
title | MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis |
title_full | MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis |
title_fullStr | MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis |
title_full_unstemmed | MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis |
title_short | MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis |
title_sort | micrornas as therapeutic targets and clinical biomarkers in atherosclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947565/ https://www.ncbi.nlm.nih.gov/pubmed/31847094 http://dx.doi.org/10.3390/jcm8122199 |
work_keys_str_mv | AT sollyemmal micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis AT dimasicatherineg micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis AT bursillchristinaa micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis AT psaltispeterj micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis AT tanjoannetm micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis |